{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Response per RECIST: CR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Response per RECIST (count): N/A"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Response per RECIST (count): PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Response per RECIST (count): SD"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"pCR original category (count): N/A"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"pCR original category (count): No"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"pCR original category (count): Yes"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Survival status at end of study (count): Alive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Survival status at end of study (count): Dead"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"To determine the clinical benefit rate (CBR) of patients with stage II or III larynx squamous cell carcinoma (SCC) after 2 cycles of pembrolizumab, cisplatin and docetaxel (PCD), and the pathologic complete response (pCR) rate after 4 cycles of PCD. The CBR rate of patients with stage II or III larynx SCC after 2 cycles of PCD is 100%, excluding one patient (measurable data not available). The pCR rate after 4 cycles of PCD is 75.0%. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v.1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), diseappearance of all target lesions; Partial Response (PR), \\>= 30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient growth to qualify for PD; Progressive Disease (PD), \\>= 20% increase in the sum of the longest diameter with an absolute increase of at least 5 mm or the appearance of new lesions","groups":[{"description":"cis 75 mg/m2 (SOC), doce 74 mg/m2 (SOC), pembro 200mg (Exp), Q3W IV","id":"OG000","title":"Experimental (Cis/Doce/Pembro)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"CBR after 2 cycles (6 weeks), pCR after 4 cycles (12 weeks), end of study (up to 3 years)","title":"CBR (After 2 Cycles of PCD) AND pCR (After 4 Cycles of PCD)","type":"PRIMARY","unitOfMeasure":"Participants"}